---
title: "Varegacestat (AL102) in Desmoid tumors: VAR-505"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: VAR-505. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 10 evidence topics quoted from 1 source."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence/var-505"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: VAR-505

<a id="heading-3.1.8"></a>

## 3.1.8 VAR-505

<a id="heading-3.1.8.1"></a>

### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

#### Relative bioavailability and bioequivalence of capsule formulations

> “A Phase 1, Open-Label, Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Varegacestat Administered in Different Dose Forms in Healthy Participants”
> “This is an open-label, randomized, crossover study to evaluate the relative bioavailability (rBA) and bioequivalence (BE) of a test capsule formulation of varegacestat compared to reference capsules formulation under fasting conditions.”

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="heading-3.1.8.2"></a>

### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

#### Registry status, dates, and site

| Study characteristic | Quoted record |
| --- | --- |
| Protocol number | “VAR-505” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Recruiting” |
| Study start (actual) | “2026-05-21” |
| Primary completion (estimated) | “2027-05” |
| Study completion (estimated) | “2027-05” |
| First posted | “2026-05-27” |
| Last update posted | “2026-10-29” |
| Site | “Celerion, Inc.”; “Tempe” |

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="heading-3.1.8.3"></a>

### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

#### Randomized, open-label, two-part crossover

| Study characteristic | Quoted record |
| --- | --- |
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Intervention model | “Crossover Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Other” |
| Part 1 sequences | “Part 1: Reference Formulation, then Test Formulation A”; “Part 1: Test Formulation A, then Reference Formulation” |
| Part 2 sequences | “Part 2: Reference Formulation, then Test Formulation B”; “Part 2: Test Formulation B, then Reference Formulation”; “Part 2: Reference Formulation, then Test Formulation C”; “Part 2: Test Formulation C, then Reference Formulation” |

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="heading-3.1.8.4"></a>

### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

#### Healthy nonsmoking adults aged 18 to 55 years

> “Healthy, adult, female of non childbearing potential or male, 18 to 55 years of age, inclusive, at the screening visit”
> “Continuous non-smoker who has not used nicotine and tobacco containing products for at least 3 months prior to the first dosing”
> “BMI ≥ 18.0 and ≤ 32.0 kg/m2 and with a body weight > 50 kg at the screening visit”
> “Able to swallow multiple capsules”

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="topic-3.1.8.4-2"></a>

#### Exclusion criteria

> “History or presence of hypersensitivity or idiosyncratic reaction to varegacestat or related compounds”
> “Liver disease or dysfunction; Gilbert's syndrome”
> “Renal dysfunction or glomerulonephritis”

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="heading-3.1.8.5"></a>

### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

#### Oral reference and test formulations

| Intervention | Quoted record |
| --- | --- |
| Reference | “Varegacestat Reference Formulation” |
| Test formulations | “Varegacestat Test Formulation A”; “Varegacestat Test Formulation B”; “Varegacestat Test Formulation C” |
| Route | “Oral administration” |

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="heading-3.1.8.6"></a>

### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

#### 3.1.8.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

<a id="topic-3.1.8.6.1-1"></a>

##### Primary endpoints: relative bioavailability by AUC and Cmax

> “Evaluate the rBA of varegacestat by AUC0-t”
> “Evaluate the rBA of varegacestat by AUC0-inf”
> “Evaluate the rBA of varegacestat by Cmax”

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="topic-3.1.8.6.1-2"></a>

##### Secondary endpoints: safety and tolerability

> “Assess the safety and tolerability of varegacestat by incidence of treatment emergent adverse events”
> “Assess the safety and tolerability of varegacestat by incidence of changes from baseline of 12-lead ECG assessments”

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="heading-3.1.8.7"></a>

### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

#### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

##### Estimated enrollment

| Study characteristic | Quoted record |
| --- | --- |
| Enrollment (estimated) | “44” |

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="heading-3.1.8.7.2"></a>

#### 3.1.8.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.8.8"></a>

### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

#### 3.1.8.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.8.8.2"></a>

#### 3.1.8.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.8.8.3"></a>

#### 3.1.8.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.8.8.4"></a>

#### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.8.8.5"></a>

#### 3.1.8.8.5 Safety Results

No evidence found.

<a id="heading-3.1.8.9"></a>

### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

#### Summary

- VAR-505 is known only from its registry record. The record lists the study as “Recruiting”, with an actual start on 2026-05-21 and estimated primary completion in 2027-05, and no results are available.
- The registry record names a reference formulation and test formulations A, B, and C without stating their strengths or composition, so the relationship between the test capsules and the capsules used in RINGSIDE or proposed for marketing cannot be determined from the record.
- The study enrolls healthy adults aged 18 to 55 years under fasting conditions, with an estimated enrollment of 44 participants.

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
